VRNA - Verona Pharma GAAP EPS of -$0.02 beats by $0.03
2023-03-07 06:14:49 ET
- Verona Pharma press release ( NASDAQ: VRNA ): Q4 GAAP EPS of -$0.02 beats by $0.03 .
- Cash and cash equivalents at December 31, 2022, were $227.8 million (December 31, 2021: $148.4 million).
- The Company believes cash and cash equivalents at December 31, 2022, the proceeds from the recent ATM sales, expected cash receipts from the UK tax credit program and funding expected to become available under the $150.0 million debt facility, will enable Verona Pharma to fund planned operating expenses and capital expenditure requirements through at least the end of 2025 including the commercial launch of ensifentrine in the US, if approved.
For further details see:
Verona Pharma GAAP EPS of -$0.02 beats by $0.03